Company Intelligence Profile
Karkinos Healthcare Private Limited
A technology-led oncology platform providing end-to-end cancer screening, diagnostics and treatment coordination across a distributed network of partner hospitals in India.
Last updated 20 August 2026
AI-generated summary from public filings and may contain errors. Verify against the detailed sections below.
Company Identity
Confirmed| Registered name | Karkinos Healthcare Private Limited |
|---|---|
| CIN | U93090MH2020PTC342527 |
| PAN | Not available in the public sources reviewed. |
| Status | Active |
| Listing | Not listed (unlisted private limited company; Reliance Industries subsidiary reportedly acquired the company per Dec-2024 press reports — not independently verified from a registry source) |
| Incorporated | 24 July 2020. Note: one WebSearch snippet paraphrased "24 Dec 2020" — likely a search-summary error |
| ROC | RoC Maharashtra (Mumbai) — Tofler |
| Sector (NIC) | Healthcare / Healthcare services / Healthcare service provider (CARE Ratings industry classification, Jan 2024); NIC code not obtained |
| Registered address | B-702, 7th Floor, Neelkanth Business Park, Kirol Village, Near Bus Depot, Vidyavihar, Mumbai, Mumbai City, Maharashtra – 400086 |
| Authorized capital | Conflicting figures across sources: Tofler states ₹20.0 lakh; treat as "partial." |
| Paid-up capital | Conflicting figures: Tofler states ₹3.0 lakh |
Business Overview
Confirmed- Karkinos Healthcare Private Limited (KHPL), founded by R. Venkatramanan (incorporated July 2020), is a technology-driven, oncology-focused healthcare platform providing end-to-end cancer care — early screening/risk assessment, diagnostics (histopathology, immunohistochemistry, molecular sequencing via its Advanced Centre for Cancer Diagnostics and Research/ACCDR labs), radiation therapy and treatment coordination — delivered through a Distributed Cancer Care Network (DCCN) of partner hospitals (~60 as of Dec 2023) across states including Maharashtra, Tamil Nadu, Kerala, Assam and Uttar Pradesh
- It operates ACCDR diagnostic centres in Mumbai, Chennai, Guwahati and Cochin (Lucknow planned), and via its 100%-owned subsidiary Karkinos Healthcare North East Private Limited (KHNEPL, incorporated 2021) is building a 150-bed multispecialty cancer hospital in Imphal, Manipur
- It holds partnerships/collaborations with Mayo Clinic (US), Tata Memorial Hospital, IIT, and a clinical-trial tie-up with Rakuten (Japan)
- was invited to present at a White House cancer-moonshot event (Oct 2022)
- and its DCCN model was acknowledged in Lancet Oncology
Directors
Partial / conflictingSource conflict noted. Tofler (with DINs): Venkataramanan Ramachandran (DIN 02504321), Sundar Raman Sethurathnam (DIN 07556277), Deepak Babulal Kharwad (DIN 08134487), Biju Thottathil Samkutty — Nominee Director (DIN 09699787). TheCompanyCheck (no DINs given) additionally/alternatively lists: Chirag Chainmal Jain, Divya Narayana Murthy, Tarang Gianchandani, Geeta Kalyandas Fulwadaya, and names Venkataramanan Ramachandran as CEO. Only two names (Venkataramanan Ramachandran; Biju Thottathil Samkutty) are corroborated across both sources — DINs for the other four TheCompanyCheck names could not be confirmed. CARE Ratings additionally names R. Venkatramanan as founder and mentions Sundar Raman and Ravi Kant (ex-MD Tata Motors) as investor-side directors/shareholders. Status: partial — DINs not obtained for the full current board.
Financials
ConfirmedFrom CARE Ratings press release dated 08-Jan-2024 (primary source, audited/unaudited as marked), figures in ₹ crore: CONSOLIDATED (KHPL + subsidiary KHNEPL): FY22(A) Total operating income 1.06, PBILDT -42.13, PAT -41.77, overall gearing 1.16x; FY23(A) Total operating income 22.17, PBILDT -147.22, PAT -143.08, overall gearing 2.50x; H1FY24(UA) Total operating income 22.60 (PBILDT/PAT not available). STANDALONE: FY22(A) income 1.06, PBILDT -42.13, PAT -41.77, gearing 1.10x; FY23(A) income 21.91, PBILDT -142.58, PAT -137.07, gearing 1.87x; H1FY24(UA) income 21.10. Management guidance: consolidated revenue envisaged at ₹195 crore for FY24. Cash and bank balance ₹186 crore as of 31-Mar-2023; total equity infused ₹450 crore till date (as of Jan 2024); KHNEPL term loan availed ₹109.10 crore. TheCompanyCheck separately claims FY2025 revenue of ₹66.93 crore (15% YoY) and paid-up capital ₹10 crore with 475 employees as of March 2024 — this conflicts in scale/timing with the CARE figures and could not be cross-verified against a second source, so it is reported as partial/unconfirmed. No standalone-vs-consolidated net worth figure was independently obtained.
Funding
Partial / conflictingReported total funding varies by aggregator (not independently verified): Tracxn cites ~$58.2M over 2 rounds from 57 investors
Charges & Loans
Partial / conflicting- TheCompanyCheck reports open charges of ₹222.54 crore and satisfied charges of ₹278.04 crore, with major lenders HDFC Bank Limited (₹210 crore) and Tata Capital Financial Services Limited (₹50 crore)
- CARE Ratings (primary) corroborates heavy debt reliance: a CARE BBB-/Stable rating on ₹250 crore of long-term fund-based bank facilities (maturity March 2032
- simple complexity
- first assigned 28-Oct-2022, reaffirmed 08-Jan-2024) at the standalone/consolidated entity for financing Linear Accelerators and PET-CT machines, and a separate ₹109.10 crore term loan drawn by subsidiary KHNEPL for the Imphal hospital (interest payments began July 2023
- principal repayment from Q1FY26)
- The two lender-amount figures from TheCompanyCheck could not be independently confirmed against a second source and are reported as partial
Credit Ratings
Confirmed- CARE Ratings Ltd (primary source, PDF press release dated 08-Jan-2024): Long-term bank facilities of ₹250 crore rated CARE BBB-
- Stable — reaffirmed (initially assigned 28-Oct-2022 at the same CARE BBB-
- Stable)
- Instrument: Fund-based–Long term, maturity March 2032, complexity "Simple." Rating done on a consolidated basis (KHPL + KHNEPL)
- No CRISIL or ICRA rating for this entity was found in any source searched — do not attribute any group entity's separate rating to KHPL
Competitors
Partial / conflicting- Named Indian oncology/cancer-care and healthtech peers: (1) HealthCare Global Enterprises (HCG) — listed, large-scale multi-city cancer hospital chain
- (2) American Oncology Institute (AOI) — mid-to-large, PE-backed cancer hospital network
- (3) Onco.com — smaller, tech-enabled oncology second-opinion/consultation platform
- (4) Cytecare Cancer Hospitals — small/mid, single-region specialty cancer hospital
- (5) MedGenome / Strand Life Sciences — mid-scale genomics/molecular diagnostics competitors to Karkinos's sequencing/ACCDR offering
- (6) Apollo Cancer Centres (part of Apollo Hospitals) — large, hospital-chain-integrated oncology vertical
- These are drawn from general sector knowledge of Indian oncology/diagnostics players, not from a scraped competitor list, so treat as indicative rather than confirmed
Frequently Asked Questions
What does Karkinos Healthcare Private Limited do?
What is the CIN of Karkinos Healthcare Private Limited?
Where is Karkinos Healthcare Private Limited registered?
When was Karkinos Healthcare Private Limited incorporated?
Looking for business funding?
Recur Club is India's largest AI-native debt platform - working capital, term loans and structured debt from 150+ lending partners, without diluting equity.